BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Puccini A, Battaglin F, Iaia ML, Lenz HJ, Salem ME. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. J Immunother Cancer 2020;8:e000404. [PMID: 32393474 DOI: 10.1136/jitc-2019-000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Paris S, Barsoumian H, Abana CO, He K, Wasley M, Younes AI, Masrorpour F, Chen D, Yang L, Dunn JD, Zhang J, Gandhi S, Nguyen QN, Cortez MA, Welsh J. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)00860-9. [PMID: 34242713 DOI: 10.1016/j.ijrobp.2021.06.041] [Reference Citation Analysis]
2 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dahiya DS, Kichloo A, Singh J, Albosta M, Lekkala M. Current immunotherapy in gastrointestinal malignancies A Review. J Investig Med 2021;69:689-96. [PMID: 33443046 DOI: 10.1136/jim-2020-001654] [Reference Citation Analysis]
4 Liu Y, Xie S, Zhu K, Guan X, Guo L, Lu R. CALD1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers. Heliyon 2021;7:e07257. [PMID: 34189308 DOI: 10.1016/j.heliyon.2021.e07257] [Reference Citation Analysis]
5 Rahma OE, Tyan K, Giobbie-Hurder A, Brohl AS, Bedard PL, Renouf DJ, Sharon E, Streicher H, Hathaway E, Cunningham R, Manos M, Severgnini M, Rodig S, Stephen Hodi F. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. J Immunother Cancer 2022;10:e003569. [PMID: 35264434 DOI: 10.1136/jitc-2021-003569] [Reference Citation Analysis]
6 Zhang Y, Zhang F, Zhao L, Fu X, Shang Y, Gao Q. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature. BMC Gastroenterol 2021;21:399. [PMID: 34688262 DOI: 10.1186/s12876-021-01950-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu XJ, Guan QL. Mechanisms of resistance to immune checkpoint inhibitors. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 857-864 [DOI: 10.11569/wcjd.v28.i17.857] [Reference Citation Analysis]
8 Mpakali A, Stratikos E. The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers (Basel) 2021;13:E134. [PMID: 33406696 DOI: 10.3390/cancers13010134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
9 Gobert AP, Boutaud O, Asim M, Zagol-Ikapitte IA, Delgado AG, Latour YL, Finley JL, Singh K, Verriere TG, Allaman MM, Barry DP, McNamara KM, Sierra JC, Amarnath V, Tantawy MN, Bimczok D, Piazuelo MB, Washington MK, Zhao S, Coburn LA, Wilson KT. Dicarbonyl Electrophiles Mediate Inflammation-Induced Gastrointestinal Carcinogenesis. Gastroenterology 2021;160:1256-1268.e9. [PMID: 33189701 DOI: 10.1053/j.gastro.2020.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Carlsen L, Huntington KE, El-deiry WS. Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers. Cancers 2022;14:1028. [DOI: 10.3390/cancers14041028] [Reference Citation Analysis]